Antiviral lead compounds from marine sponges

Marine Drugs

Volumn 8, Issue 10, 2010, Pages 2619-2638

  Sagar, Sunil ^a   Kaur, Mandeep ^a   Minneman, Kenneth P ^a  

^a KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

Antiviral; Metagenomics; Natural products; Sponge

Indexed keywords

4 METHYLAAPTAMINE; ACICLOVIR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; AVAROL; CYCLODEPSIPEPTIDE; DNA POLYMERASE; DRAGMACIDIN F; MANZAMINE A; MICROSPINOSAMIDE; MYCALAMIDE A; MYCALAMIDE B; NATURAL PRODUCT; ORGANOLEAD COMPOUND; PAPUAMIDE A; PAPUAMIDE B; PAPUAMIDE C; PAPUAMIDE D; UNCLASSIFIED DRUG; VIDARABINE;

AAPTOS; ANTIVIRAL ACTIVITY; CONCENTRATION RESPONSE; DNA SYNTHESIS INHIBITION; DRUG ISOLATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HALICLONA; HALICORTEX; HERPES SIMPLEX VIRUS; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS; METAGENOMICS; NONHUMAN; PACHYPELLINA; REVIEW; SIDONOPS MICROSPINOSA; SPONGE (PORIFERA); TETHYA CRYPTA; THEONELLA; VACCINIA VIRUS; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS RESISTANCE; VIRUS STRAIN;

ARA; HERPES; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS; SIMPLEXVIRUS; TETHYA CRYPTA;

EID: 78049442987     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md8102619     Document Type: Review

References (131)

1. Bergquist, P. Sponges; Univ of California Press: Berkeley, CA, USA, 1978.
2. Newman, D.; Cragg, G. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 2004, 67, 1216-1238. (Pubitemid 39145623)
3. Sarma, A.S.; Daum, T.; Miiller, W.E.G. Secondary Metabolites from Marine Sponges; Ullstein-Mosby Verlag: Berlin, Germany, 1993.
4. Faulkner, D.J. Marine natural products. Nat. Prod. Rep. 2002, 19, 1-48.
5. Bergmann, W.; Feeney, R.J. The isolation of a new thymine pentoside from sponges. J. Am. Chem. Soc. 1950, 72, 2809-2810.
6. Bergmann, W.; Feeney, R.J. Contributions to the study of marine products. XXXII. The nucelosides of sponges. I. J. Org. Chem. 1951, 16, 981-987.
7. Shepp, D.H.; Dandliker, P.S.; Meyers, J.D. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N. Engl. J. Med. 1986, 314, 208-212.
8. Whitley, R.J.; Gnann, J.W., Jr.; Hinthorn, D.; Liu, C.; Pollard, R.B.; Hayden, F.; Mertz, G.J.; Oxman, M.; Soong, S.J. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J. Infect. Dis. 1992, 165, 450-455.
9. Blunt, J.W.; Copp, B.R.; Munro, M.H.; Northcote, P.T.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2005, 22, 15-61.
10. Privat de Garilhe, M.; de Rudder, J. Effect of 2 arbinose nucleosides on the multiplication of herpes virus and vaccine in cell culture. C. R. Hebd. Seances Acad. Sci. 1964, 259, 2725-2728.
11. Field, H.; De Clercq, E. Antiviral drugs-a short history of their discovery and development. Microbiol. Today 2004, 31, 58-61.
12. Mayer, A.M.S.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 2010, 31(6), 255-265.
13. Shope, T.C.; Kauffman, R.E.; Bowman, D.; Marcus, E.L. Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. J. Infect. Dis. 1983, 148, 721-725.
14. Sloan, B.; Kielty, J.; Miller, F. Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication. Ann. N.Y. Acad. Sci. 1977, 284, 60.
15. Whitley, R.; Tucker, B.; Kinkel, A.; Barton, N.; Pass, R.; Whelchel, J.; Cobbs, C.; Diethelm, A.; Buchanan, R. Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans. Antimicrob. Agents Chemother. 1980, 18, 709.
16. Kamiyama, T.; Kurokawa, M.; Shiraki, K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J. Gen. Virol. 2001, 82, 2761-2765.
17. Shiraki, K.; Namazue, J.; Okuno, T.; Yamanishi, K.; Takahashi, M. Novel sensitivity of acyclovir-resistant varicella-zoster virus to anti-herpetic drugs. Antiviral Chem. Chemother. 1990, 1, 373-375.
18. Doering, A.; Keller, J.; Cohen, S. Some effects of D-arabinosyl nucleosides on polymer syntheses in mouse fibroblasts. Cancer Res. 1966, 26, 2444.
19. Plunkett, W.; Cohen, S.S. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells. Cancer Res. 1975, 35, 1547-1554.
20. Dicioccio, R.A.; Srivastava, B.I. Kinetics of inhibition of deoxynucleotide-polymerizing enzyme activities from normal and leukemic human cells by 9-beta-D-arabinofuranosyladenine 5′-triphosphate and 1-beta-D-arabinofuranosylcytosine 5′-triphosphate. Eur. J. Biochem. 1977, 79, 411-418.
21. Rose, K.; Jacob, S. Selective inhibition of RNA polyadenylation by Ara-ATP in vitro: a possible mechanism for antiviral action of Ara-A. Biochem. Biophys. Res. Commun. 1978, 81, 1418-1424.
22. Hilfinger, J.M.; W.Z., Kim, J.; Mitchell, S.; Breitenbach, J.; Amidon, G.; Drach, J. Vidarabine Prodrugs as Anti-Pox Virus Agents. Antiviral Res. 2006, 70, A14.
23. Wang, Z.; Prudhomme, D.; Buck, J.; Park, M.; Rizzo, C. Stereocontrolled Syntheses of Deoxyribonucleosides via Photoinduced Electron-Transfer Deoxygenation of Benzoyl-Protected Ribo-and Arabinonucleosides. J. Org. Chem. 2000, 65, 5969-5985.
24. Darzynkiewicz, E.; Kazimierczuk, Z.; Shugar, D. Preparation and properties of the O-methyl derivatives of 9-beta-D-arabinofuranosyladenine. Cancer Biochem. Biophys. 1976, 1, 203-209.
25. Kotra, L.; Manouilov, K.; Cretton-Scott, E.; Sommadossi, J.; Boudinot, F.; Schinazi, R.; Chu, C. Synthesis, biotransformation, and pharmacokinetic studies of 9-(D-arabinofuranosyl)-6- azidopurine: A prodrug for Ara-A designed to utilize the azide reduction pathway. J. Med. Chem. 1996, 39, 5202-5207.
26. McGuigan, C.; Shackleton, J.; Tollerfield, S.; Riley, P. Synthesis and evaluation of some novel phosphate and phosphinate derivatives of araA. Studies on the mechanism of action of phosphate triesters. Nucleic Acids Res. 1989, 17, 10171-10177.
27. Suhadolnik, R.; Pornbanlualap, S.; Wu, J.; Baker, D.; Hebbler, A. Biosynthesis of 9-[beta]- arabinofuranosyladenine: Hydrogen exchange at C-2′and oxygen exchange at C-3′of adenosine* 1. Arch. Biochem. Biophys. 1989, 270, 363-373.
28. Perry, N.; Blunt, J.; Munro, M.; Pannell, L. Mycalamide A, an antiviral compound from a New Zealand sponge of the genus Mycale. J. Am. Chem. Soc. 1988, 110, 4850-4851.
29. Perry, N.B.; Blunt, J.W.; Munro, M.H.G.; Thompson, A.M. Antiviral and antitumor agents from a New Zealand sponge, Mycale sp. 2. Structures and solution conformations of mycalamides A and B. J. Org. Chem. 1990, 55, 223-227.
30. Burres, N.; Clement, J. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and-B and onnamide. Cancer Res. 1989, 49, 2935.
31. Gurel, G.; Blaha, G.; Steitz, T.; Moore, P. The structures of Triacetyloleandomycin and Mycalamide A bound to the large ribosomal subunit of Haloarcula marismortui. Antimicrob. Agents Chemother. 2009, 53, 5010-5014.
32. Kagawa, N.; Ihara, M.; Toyota, M. Total Synthesis of (+)-Mycalamide A. Org. Lett. 2006, 8, 875-878.
33. Sohn, J.; Waizumi, N.; Zhong, H.; Rawal, V. Total synthesis of mycalamide A. J. Am. Chem. Soc 2005, 127, 7290-7291.
34. Toyota, M.; Hirota, M.; Hirano, H.; Ihara, M. A stereoselective synthesis of the C-10 to C-18 (right-half) fragment of mycalamides employing lewis acid promoted intermolecular aldol reaction. Org. Lett. 2000, 2, 2031-2034.
35. Trost, B.; Yang, H.; Probst, G. A formal synthesis of (-)-mycalamide A. J. Am. Chem. Soc. 2004, 126, 48-49.
36. Hagiwara, K.; Kondoh, Y.; Ueda, A.; Yamada, K.; Goto, H.; Watanabe, T.; Nakata, T.; Osada, H.; Aida, Y. Discovery of novel antiviral agents directed against the influenza A virus nucleoprotein using photo-cross-linked chemical arrays. Biochem. Biophys. Res. Commun. 2010. 394(3), 721-727.
37. Minale, L.; Riccio, R.; Sodano, G. Avarol a novel sesquiterpenoid hydroquinone with a rearranged drimane skeleton from the sponge. Tetrahedron Lett. 1974, 15, 3401-3404.
38. Rosa, S.; Minale, L.; Riccio, R.; Sodano, G. The absolute configuration of avarol, a rearranged sesquiterpenoid hydroquinone from a marine sponge. J. Chem. Soc. Perkin Trans. 1 1976, 1976, 1408-1414.
39. Sarma, A.; Chattopadhyay, P. Synthetic studies of trans-clerodane diterpenoids and congeners: stereocontrolled total synthesis of (±)-avarol. J. Org. Chem. 1982, 47, 1727-1731.
40. Sarin, P.; Sun, D.; Thornton, A.; Muller, W. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone. J. Natl. Cancer Inst. 1987, 78, 663-666.
41. Batke, E.; Ogura, R.; Vaupel, P.; Hummel, K.; Kallinowski, F.; Gasić, M.J.; Schröder, H.; Müllerm, W. Action of the antileukemic and anti-HTLV-III (anti-HIV) agent avarol on the levels of superoxide dismutases and glutathione peroxidase activities in L5178y mouse lymphoma cells. Cell Biochem. Funct. 1988, 6, 123-129.
42. Kuchino, Y.; Nishimura, S.; Schröder, H.; Rottmann, M.; Müller, W. Selective inhibition of formation of suppressor glutamine tRNA in Moloney murine leukemia virus-infected NIH-3T3 cells by Avarol. Virology 1988, 165, 518-526.
43. Muller, W.; Schroder, H. Cell biological aspects of HIV-1 infection: effects of the anti-HIV-1 agent avarol. Int. J. Sports Med. 1991, 12, S43-49.
44. Muller, W.E.; Schroder, H.C.; Reuter, P.; Sarin, P.S.; Hess, G.; Meyer zum Buschenfelde, K.H.; Kuchino, Y.; Nishimura, S. Inhibition of expression of natural UAG suppressor glutamine tRNA in HIV-infected human H9 cells in vitro by Avarol. AIDS Res. Hum. Retroviruses 1988, 4, 279-286.
45. Loya, S.; Hizi, A. The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives. FEBS Lett. 1990, 269, 131-134.
46. Schröder, H.; Bégin, M.; Klöcking, R.; Matthes, E.; Sarma, A.; Gašić, M.; Müller, W. Avarol restores the altered prostaglandin and leukotriene metabolism in monocytes infected with human immunodeficiency virus type 1. Virus Res. 1991, 21, 213-223.
47. Sarin, P.; Sun, D.; Thornton, A.; Miller, W. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone. J. Natl. Cancer Inst. 1987, 78, 663.
48. De Giulio, A.; De Rosa, S.; Strazzulo, G.; Diliberto, L.; Obino, P.; Marongiu, M.E.; Pani, A.; La Colla, P. Synthesis and evaluation of cytostatic and antiviral activities of 3′and 4′-avarone derivatives. Antiviral Chem. Chemother. 1991, 2, 223-227.
49. Suhadolnik, R.; Pornbanlualap, S.; Baker, D.; Tiwari, K.; Hebbler, A. Stereospecific 2′-amination and 2′-chlorination of adenosine by Actinomadura in the biosynthesis of 2′-amino-2′- deoxyadenosine and 2′-chloro-2′-deoxycoformycin* 1. Arch. Biochem. Biophys. 1989, 270, 374-382.
50. Ling, T.; Xiang, A.; Theodorakis, E. Enantioselective total synthesis of avarol and avarone. Angew. Chem. Int. Ed. 1999, 38, 3089-3091. (Pubitemid 29513696)
51. Muller, W.; Bohm, M.; Batel, R.; De Rosa, S.; Tommonaro, G.; Muller, I.; Schroder, H. Application of cell culture for the production of bioactive compounds from sponges: synthesis of avarol by primmorphs from Dysidea avara. J. Nat. Prod. 2000, 63, 1077-1081.
52. Müller, W.; Grebenjuk, V.; Le Pennec, G.; Schröder, H.; Brümmer, F.; Hentschel, U.; Müller, I.; Breter, H. Sustainable production of bioactive compounds by sponges - cell culture and gene cluster approach: a review. Mar. Biotechnol. 2004, 6, 105-117.
53. Ford, P.; Gustafson, K.; McKee, T.; Shigematsu, N.; Maurizi, L.; Pannell, L.; Williams, D.; de Silva, E.; Lassota, P.; Allen, T. Papuamides A-D, HIV-Inhibitory and Cytotoxic Depsipeptides from the Sponges Theonella mirabilis and Theonella swinhoei Collected in Papua New Guinea. J. Am. Chem. Soc. 1999, 121, 5899-5909.
54. Xie, W.; Ding, D.; Zi, W.; Li, G.; Ma, D. Total Synthesis and Structure Assignment of Papuamide B, A Potent Marine Cyclodepsipeptide with Anti-HIV Properties13. Angew. Chem. Int. Ed. 2008, 47, 2844-2848.
55. Andjelic, C.; Planelles, V.; Barrows, L. Characterizing the Anti-HIV Activity of Papuamide A. Mar. Drugs 2008, 6, 528-549.
56. Esté, J.; Telenti, A. HIV entry inhibitors. Lancet 2007, 370, 81-88.
57. Volpon, L.; Besson, F.; Lancelin, J. NMR structure of active and inactive forms of the sterol-dependent antifungal antibiotic bacillomycin L. Eur. J. Biochem. 2001, 264, 200-210.
58. Rashid, M.; Gustafson, K.; Cartner, L.; Shigematsu, N.; Pannell, L.; Boyd, M. Microspinosamide, a new HIV-inhibitory cyclic depsipeptide from the marine sponge Sidonops microspinosa1. J. Nat. Prod. 2001, 64, 117-121.
59. Boyd, M. AIDS Etiology, Diagnosis, Treatment and Prevention; De Vita, V.T., Jr., Hellman, S., Rosenberg, S.A., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 1988; pp. 305-319.
60. Valeria D'Auria, M.; Zampella, A.; Paloma, L.G.; Minale, L.; Debitus, C.; Roussakis, C.; Le Bert, V. Callipeltins B and C; bioactive peptides from a marine Lithistida sponge Callipelta sp. Tetrahedron 1996, 52, 9589-9596.
61. Zampella, A.; D'Auria, M.; Paloma, L.; Casapullo, A.; Minale, L.; Debitus, C.; Henin, Y. Callipeltin A, an anti-HIV cyclic depsipeptide from the New Caledonian Lithistida sponge Callipelta sp. J. Am. Chem. Soc. 1996, 118, 6202-6209.
62. Coutinho, A.F.; Chanas, B.; e Souza, T.M.L.; Frugrulhetti, I.C.P.P.; de A Epifanio, R. Anti HSV-1 alkaloids from a feeding deterrent marine sponge of the genus Aaptos. Heterocycles 2002, 57, 1265-1272.
63. Souza, T.; Abrantes, J.; de AEpifanio, R.; Fontes, C.; Frugulhetti, I. The Alkaloid 4-Methylaaptamine Isolated from the Sponge Aaptos aaptos Impairs Herpes simplex Virus Type 1 Penetration and Immediate-Early Protein Synthesis. Planta Med. 2007, 73, 200-205.
64. Nakamura, H.; Kobayashi, J.; Ohizumi Yoshimasa, Y. Isolation and structure of aaptamine a novel heteroaromatic substance possessing [alpha]-blocking activity from the sea sponge. Tetrahedron Lett. 1982, 23, 5555-5558.
65. Pettit, G.; Hoffmann, H.; Herald, D.; McNulty, J.; Murphy, A.; Higgs, K.; Hamel, E.; Lewin, N.; Pearce, L.; Blumberg, P. Antineoplastic agents 491. Synthetic conversion of aaptamine to isoaaptamine, 9-demethylaaptamine, and 4-methylaaptamine. J. Org. Chem. 2004, 69, 2251-2256.
66. Gul, W.; Hammond, N.; Yousaf, M.; Bowling, J.; Schinazi, R.; Wirtz, S.; de Castro Andrews, G.; Cuevas, C.; Hamann, M. Modification at the C9 position of the marine natural product isoaaptamine and the impact on HIV-1, mycobacterial, and tumor cell activity. Bioorg. Med. Chem. 2006, 14, 8495-8505.
67. Cutignano, A.; Bifulco, G.; Bruno, I.; Casapullo, A.; Gomez-Paloma, L.; Riccio, R. Dragmacidin F: A New Antiviral Bromoindole Alkaloid from the Mediterranean Sponge Halicortex sp. Tetrahedron 2000, 56, 3743-3748.
68. Garg, N.; Caspi, D.; Stoltz, B. The total synthesis of (+)-dragmacidin F. J. Am. Chem. Soc. 2004, 126, 9552-9553.
69. Sakai, R.; Higa, T.; Jefford, C.W.; Bernardinelli, G. Manzamine A, a novel antitumor alkaloid from a sponge. J. Am. Chem. Soc. 1986, 108, 6404-6405.
70. El Sayed, K.A.; Kelly, M.; Kara, U.A.K.; Ang, K.K.H.; Katsuyama, I.; Dunbar, D.C.; Khan, A.A.; Hamann, M.T. New Manzamine Alkaloids with Potent Activity against Infectious Diseases. J. Am. Chem. Soc. 2001, 123, 1804-1808.
71. Rao, K.V.; Santarsiero, B.D.; Mesecar, A.D.; Schinazi, R.F.; Tekwani, B.L.; Hamann, M.T. New Manzamine Alkaloids with Activity against Infectious and Tropical Parasitic Diseases from an Indonesian Sponge. J. Nat. Prod. 2003, 66, 823-828.
72. Ang, K.; Holmes, M.; Higa, T.; Hamann, M.; Kara, U. In vivo antimalarial activity of the beta-carboline alkaloid manzamine A. Antimicrob. Agents Chemother. 2000, 44, 1645.
73. Peng, J.; Shen, X.; El Sayed, K.; Dunbar, D.; Perry, T.; Wilkins, S.; Hamann, M.; Bobzin, S.; Huesing, J.; Camp, R. Marine natural products as prototype agrochemical agents. J. Agric. Food Chem. 2003, 51, 2246-2252.
74. Peng, J.; Rao, K.; Choo, Y.; Hamann, M. Manzamine Alkaloids. In Modern Alkaloids: Structure, Isolation, Synthesis and Biology; Fattorusso, E., Taglialatela-Scafati, O., Eds.; Wiley: Weinheim, Germany, 2007; pp. 189-231.
75. Ichiba, T.; Corgiat, J.; Scheuer, P.; Kelly-Borges, M. 8-Hydroxymanzamine A, a beta-carboline alkaloid from a sponge, Pachypellina sp. J. Nat. Prod. 1994, 57, 168-170.
76. Edrada, R.; Proksch, P.; Wray, V.; Witte, L.; Muller, W.; van Soest, R. Four new bioactive manzamine-type alkaloids from the Philippine marine sponge Xestospongia ashmorica. J. Nat. Prod. 1996, 59, 1056-1060.
77. Rao, K.; Santarsiero, B.; Mesecar, A.; Schinazi, R.; Tekwani, B.; Hamann, M. New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge. J. Nat. Prod. 2003, 66, 823-828.
78. Samoylenko, V.; Khan, S.; Jacob, M.; Tekwani, B.; Walker, L.; Hufford, C.; Muhammad, I. Bioactive (+)-Manzamine A and (+)-Hydroxymanzamine A Tertiary Bases and Salts from Acanthostrongylophora ingens and Their Preparations. Nat. Prod. Commun. 2009, 4, 185-192.
79. Humphrey, J.; Liao, Y.; Ali, A.; Rein, T.; Wong, Y.; Chen, H.; Courtney, A.; Martin, S. Enantioselective total syntheses of manzamine A and related alkaloids. J. Am. Chem. Soc. 2002, 124, 8584-8592.
80. Yousaf, M.; Hammond, N.; Peng, J.; Wahyuono, S.; McIntosh, K.; Charman, W.; Mayer, A.; Hamann, M. New manzamine alkaloids from an Indo-Pacific sponge. Pharmacokinetics, oral availability, and the significant activity of several manzamines against HIV-I, AIDS opportunistic infections, and inflammatory diseases. J. Med. Chem. 2004, 47, 3512-3517.
81. Clive, D.L.J.; Wang, J. Stereospecific Total Synthesis of the Antiviral Agent Hamigeran B - Use of Large Silyl Groups to Enforce Facial Selectivity and to Suppress Hydrogenolysis13. Angew. Chem. Int. Ed. 2003, 42, 3406-3409.
82. Trost, B.; Pissot-Soldermann, C.; Chen, I.; Schroeder, G. An asymmetric synthesis of hamigeran B via a Pd asymmetric allylic alkylation for enantiodiscrimination. J. Am. Chem. Soc. 2004, 126, 4480-4481.
83. Trost, B.M.; Pissot-Soldermann, C.; Chen, I. A short and concise asymmetric synthesis of hamigeran B. Chemistry 2005, 11, 951-959.
84. da Silva, A.; Kratz, J.; Farias, F.; Henriques, A.; dos SANTOS, J.; Leonel, R.; Lerner, C.; Mothes, B.; Barardi, C.; Simões, C. In vitro antiviral activity of marine sponges collected off Brazilian coast. Biol. Pharm. Bull. 2006, 29, 135-140.
85. Proksch, P.; Edrada, R.; Ebel, R. Drugs from the seas-current status and microbiological implications. Appl. Microbiol. Biotechnol. 2002, 59, 125-134.
86. Hart, J.; Lill, R.; Hickford, S.; Blunt, J.; Munro, M. The halichondrins: chemistry, biology, supply and delivery. Drugs Sea 2000, 134-153.
87. Wall, M.; Wani, M. Camptothecin and taxol: discovery to clinic - thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1995, 55, 753-760.
88. Belarbi, E.; Gómez, C. Producing drugs from marine sponges. Biotechnol. Adv. 2003, 21, 585-598.
89. Flowers, A.; Garson, M.; Webb, R.; Dumdei, E.; Charan, R. Cellular origin of chlorinated diketopiperazines in the dictyoceratid sponge Dysidea herbacea (Keller). Cell Tissue Res. 1998, 292, 597-607.
90. Ridley, C.; Bergquist, P.; Harper, M.; Faulkner, D.; Hooper, J.; Haygood, M. Speciation and biosynthetic variation in four dictyoceratid sponges and their cyanobacterial symbiont, Oscillatoria spongeliae. Chem. Biol. 2005, 12, 397-406.
91. Unson, M.; Holland, N.; Faulkner, D. A brominated secondary metabolite synthesized by the cyanobacterial symbiont of a marine sponge and accumulation of the crystalline metabolite in the sponge tissue. Mar. Biol. 1994, 119, 1-11.
92. Taylor, M.; Radax, R.; Steger, D.; Wagner, M. Sponge-associated microorganisms: evolution, ecology, and biotechnological potential. Microbiol. Mol. Biol. Rev. 2007, 71, 295.
93. Dieckmann, R.; Graeber, I.; Kaesler, I.; Szewzyk, U.; von Doehren, H. Rapid screening and dereplication of bacterial isolates from marine sponges of the Sula Ridge by intact-cell-MALDITOF mass spectrometry (ICM-MS). Appl. Microbiol. Biotechnol. 2005, 67, 539-548.
94. Gunasekera, A.; Sfanos, K.; Harmody, D.; Pomponi, S.; McCarthy, P.; Lopez, J. HBMMD: an enhanced database of the microorganisms associated with deeper water marine invertebrates. Appl. Microbiol. Biotechnol. 2005, 66, 373-376.
95. Staley, J.; Konopka, A. Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats. Annu. Rev. Microbiol. 1985, 39, 321-346.
96. Webster, N.; Hill, R. The culturable microbial community of the Great Barrier Reef sponge Rhopaloeides odorabile is dominated by an -Proteobacterium. Mar. Biol. 2001, 138, 843-851.
97. Webster, N.; Wilson, K.; Blackall, L.; Hill, R. Phylogenetic diversity of bacteria associated with the marine sponge Rhopaloeides odorabile. Appl. Environ. Microbiol. 2001, 67, 434.
98. Olson, J.; Lord, C.; McCarthy, P. Improved recoverability of microbial colonies from marine sponge samples. Microb. Ecol. 2000, 40, 139-147.
99. Burja, A.; Webster, N.; Murphy, P.; Hill, R. Microbial symbionts of Great Barrier Reef sponges. Mem. Queensl. Mus. 1999, 44, 63-76.
100. Taylor, M.; Radax, R.; Steger, D.; Wagner, M. Sponge-associated microorganisms: evolution, ecology, and biotechnological potential. Microbiol. Mol. Biol. Rev. 2007, 71, 295-307.
101. Duckworth, A. Farming Sponges to Supply Bioactive Metabolites and Bath Sponges: A Review. Mar. Biotechnol. 2009, 11, 669-679.
102. Koopmans, M.; Martens, D.; Wijffels, R. Towards Commercial Production of Sponge Medicines. Mar. Drugs. 2009, 7, 787-802.
103. Wijffels, R. Potential of sponges and microalgae for marine biotechnology. Trends Biotechnol. 2008, 26, 26-31.
104. Kennedy, J.; Marchesi, J.; Dobson, A. Metagenomic approaches to exploit the biotechnological potential of the microbial consortia of marine sponges. Appl. Microbiol. Biotechnol. 2007, 75, 11-20. (Pubitemid 46669238)
105. Handelsman, J. Metagenomics: Application of Genomics to Uncultured Microorganisms. Microbiol. Mol. Biol. Rev. 2004, 68, 669-685.
106. Kim, T.K.; Fuerst, J.A. Diversity of polyketide synthase genes from bacteria associated with the marine sponge Pseudoceratina clavata: culture-dependent and culture-independent approaches. Environ. Microbiol. 2006, 8, 1460-1470.
107. Schirmer, A.; Gadkari, R.; Reeves, C.D.; Ibrahim, F.; DeLong, E.F.; Hutchinson, C.R. Metagenomic Analysis Reveals Diverse Polyketide Synthase Gene Clusters in Microorganisms Associated with the Marine Sponge Discodermia dissoluta. Appl. Environ. Microbiol. 2005, 71, 4840-4849.
108. Rachid, S.; Krug, D.; Kunze, B.; Kochems, I.; Scharfe, M.; Zabriskie, T.M.; Blöcker, H.; Müller, R. Molecular and Biochemical Studies of Chondramide Formation - Highly Cytotoxic Natural Products from Chondromyces crocatus Cm c5. Chem. Biol. 2006, 13, 667-681.
109. Fieseler, L.; Horn, M.; Wagner, M.; Hentschel, U. Discovery of the Novel Candidate Phylum "Poribacteria" in Marine Sponges. Appl. Environ. Microbiol. 2004, 70, 3724-3732.
110. Fieseler, L.; Quaiser, A.; Schleper, C.; Hentschel, U. Analysis of the first genome fragment from the marine sponge-associated, novel candidate phylum Poribacteria by environmental genomics. Environ. Microbiol. 2006, 8, 612-624.
111. Gross, F.; Ring, M.; Perlova, O.; Fu, J.; Schneider, S.; Gerth, K.; Kuhlmann, S.; Stewart, A.; Zhang, Y.; Müller, R. Metabolic engineering of Pseudomonas putida for methylmalonyl-CoA biosynthesis to enable complex heterologous secondary metabolite formation. Chem. Biol. 2006, 13, 1253-1264.
112. Wenzel, S.; Gross, F.; Zhang, Y.; Fu, J.; Stewart, A.; Müller, R. Heterologous expression of a myxobacterial natural products assembly line in pseudomonads via red/ET recombineering. Chem. Biol. 2005, 12, 349-356.
113. Khosla, C.; Keasling, J. Metabolic engineering for drug discovery and development. Nat. Rev. Drug Discov. 2003, 2, 1019-1025.
114. Mutka, S.; Carney, J.; Liu, Y.; Kennedy, J. Heterologous Production of Epothilone C and D in Escherichia coli. Biochemistry 2006, 45, 1321-1330.
115. Newman, J.; Marshall, J.; Chang, M.; Nowroozi, F.; Paradise, E.; Pitera, D.; Newman, K.; Keasling, J. High-level production of amorpha-4, 11-diene in a two-phase partitioning bioreactor of metabolically engineered Escherichia coli. Biotechnol. Bioeng. 2006, 95, 684-691.
116. Julien, B.; Shah, S. Heterologous expression of epothilone biosynthetic genes in Myxococcus xanthus. Antimicrob. Agents Chemother. 2002, 46, 2772.
117. Pfeifer, B.; Khosla, C. Biosynthesis of polyketides in heterologous hosts. Microbiol. Mol. Biol. Rev. 2001, 65, 106.
118. Long, P.; Dunlap, W.; Battershill, C.; Jaspars, M. Shotgun cloning and heterologous expression of the patellamide gene cluster as a strategy to achieving sustained metabolite production. ChemBioChem 2005, 6, 1760-1765.
119. Brady, S.; Chao, C.; Clardy, J. New natural product families from an environmental DNA (eDNA) gene cluster. J. Am. Chem. Soc. 2002, 124, 9968-9969.
120. Brady, S.; Chao, C.; Handelsman, J.; Clardy, J. Cloning and heterologous expression of a natural product biosynthetic gene cluster from eDNA. Org. Lett. 2001, 3, 1981-1984.
121. Gillespie, D.; Brady, S.; Bettermann, A.; Cianciotto, N.; Liles, M.; Rondon, M.; Clardy, J.; Goodman, R.; Handelsman, J. Isolation of antibiotics turbomycin A and B from a metagenomic library of soil microbial DNA. Appl. Environ. Microbiol. 2002, 68, 4301.
122. MacNeil, I.; Tiong, C.; Minor, C.; August, P.; Grossman, T.; Loiacono, K.; Lynch, B.; Phillips, T.; Narula, S.; Sundaramoorthi, R. Expression and isolation of antimicrobial small molecules from soil DNA libraries. J. Mol. Microbiol. Biotechnol. 2001, 3, 301-308.
123. Sipkema, D.; Franssen, M.; Osinga, R.; Tramper, J.; Wijffels, R. Marine sponges as pharmacy. Mar. Biotechnol. 2005, 7, 142-162.
124. Piel, J.; Hui, D.; Wen, G.; Butzke, D.; Platzer, M.; Fusetani, N.; Matsunaga, S. Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei. Proc. Natl. Acad. Sci. USA 2004, 101, 16222.
125. Sudek, S.; Lopanik, N.; Waggoner, L.; Hildebrand, M.; Anderson, C.; Liu, H.; Patel, A.; Sherman, D.; Haygood, M. Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus Endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina. J. Nat. Prod. 2007, 70, 67-74.
126. Fortman, J.L.; Sherman, D.H. Utilizing the Power of Microbial Genetics to Bridge the Gap Between the Promise and the Application of Marine Natural Products. ChemBioChem 2005, 6, 960-978.
127. Taylor, M.W.; Radax, R.; Steger, D.; Wagner, M. Sponge-Associated Microorganisms: Evolution, Ecology, and Biotechnological Potential. Microbiol. Mol. Biol. Rev. 2007, 71, 295-347.
128. Wang, G. Diversity and biotechnological potential of the sponge-associated microbial consortia. J. Ind. Microbiol. Biotechnol. 2006, 33, 545-551.
129. Fisch, K.; Gurgui, C.; Heycke, N.; van der Sar, S.; Anderson, S.; Webb, V.; Taudien, S.; Platzer, M.; Rubio, B.; Robinson, S. Polyketide assembly lines of uncultivated sponge symbionts from structure-based gene targeting. Nat. Chem. Biol. 2009, 5, 494-501.
130. Hochmuth, T.; Piel, J. Polyketide synthases of bacterial symbionts in sponges-Evolution-based applications in natural products research. Phytochemistry 2009, 70, 1841-1849.
131. Zhang, L.; An, R.; Wang, J.; Sun, N.; Zhang, S.; Hu, J.; Kuai, J. Exploring novel bioactive compounds from marine microbes. Curr. Opin. Microbiol. 2005, 8, 276-281. (Pubitemid 40813069)